Logo image of TWST

TWIST BIOSCIENCE CORP (TWST) Stock Fundamental Analysis

NASDAQ:TWST - Nasdaq - US90184D1000 - Common Stock - Currency: USD

28.26  +0.1 (+0.36%)

After market: 28.005 -0.26 (-0.9%)

Fundamental Rating

4

Overall TWST gets a fundamental rating of 4 out of 10. We evaluated TWST against 560 industry peers in the Biotechnology industry. TWST has a great financial health rating, but its profitability evaluates not so good. TWST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TWST had negative earnings in the past year.
TWST had a negative operating cash flow in the past year.
TWST had negative earnings in each of the past 5 years.
In the past 5 years TWST always reported negative operating cash flow.
TWST Yearly Net Income VS EBIT VS OCF VS FCFTWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

TWST has a better Return On Assets (-32.09%) than 63.88% of its industry peers.
TWST has a Return On Equity of -43.43%. This is in the better half of the industry: TWST outperforms 68.33% of its industry peers.
Industry RankSector Rank
ROA -32.09%
ROE -43.43%
ROIC N/A
ROA(3y)-27.66%
ROA(5y)-27.95%
ROE(3y)-34.86%
ROE(5y)-34.47%
ROIC(3y)N/A
ROIC(5y)N/A
TWST Yearly ROA, ROE, ROICTWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

TWST's Gross Margin of 46.70% is fine compared to the rest of the industry. TWST outperforms 75.80% of its industry peers.
In the last couple of years the Gross Margin of TWST has grown nicely.
TWST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y27.06%
TWST Yearly Profit, Operating, Gross MarginsTWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TWST has been increased compared to 1 year ago.
Compared to 5 years ago, TWST has more shares outstanding
TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TWST Yearly Shares OutstandingTWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TWST Yearly Total Debt VS Total AssetsTWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.70 indicates that TWST is not in any danger for bankruptcy at the moment.
TWST's Altman-Z score of 3.70 is fine compared to the rest of the industry. TWST outperforms 77.58% of its industry peers.
TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.7
ROIC/WACCN/A
WACC9.55%
TWST Yearly LT Debt VS Equity VS FCFTWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 4.51 indicates that TWST has no problem at all paying its short term obligations.
The Current ratio of TWST (4.51) is comparable to the rest of the industry.
A Quick Ratio of 4.24 indicates that TWST has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.24, TWST is in line with its industry, outperforming 50.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.51
Quick Ratio 4.24
TWST Yearly Current Assets VS Current LiabilitesTWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

TWST shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.83%.
Looking at the last year, TWST shows a very strong growth in Revenue. The Revenue has grown by 25.29%.
TWST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.90% yearly.
EPS 1Y (TTM)-3.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.46%
Revenue 1Y (TTM)25.29%
Revenue growth 3Y33.24%
Revenue growth 5Y41.9%
Sales Q2Q%23.23%

3.2 Future

Based on estimates for the next years, TWST will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.70% on average per year.
Based on estimates for the next years, TWST will show a quite strong growth in Revenue. The Revenue will grow by 18.17% on average per year.
EPS Next Y38.46%
EPS Next 2Y26.3%
EPS Next 3Y19.63%
EPS Next 5Y13.7%
Revenue Next Year21.06%
Revenue Next 2Y19.34%
Revenue Next 3Y18.9%
Revenue Next 5Y18.17%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TWST Yearly Revenue VS EstimatesTWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
TWST Yearly EPS VS EstimatesTWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TWST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TWST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TWST Price Earnings VS Forward Price EarningsTWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TWST Per share dataTWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

TWST's earnings are expected to grow with 19.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.3%
EPS Next 3Y19.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TWST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TWIST BIOSCIENCE CORP

NASDAQ:TWST (5/23/2025, 9:00:41 PM)

After market: 28.005 -0.26 (-0.9%)

28.26

+0.1 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners110.82%
Inst Owner Change3.68%
Ins Owners1.48%
Ins Owner Change2.65%
Market Cap1.69B
Analysts81.05
Price Target52.5 (85.77%)
Short Float %17.05%
Short Ratio7.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.88%
Min EPS beat(2)-12.39%
Max EPS beat(2)18.15%
EPS beat(4)2
Avg EPS beat(4)-16.01%
Min EPS beat(4)-88.34%
Max EPS beat(4)18.55%
EPS beat(8)6
Avg EPS beat(8)-0.86%
EPS beat(12)10
Avg EPS beat(12)7.15%
EPS beat(16)12
Avg EPS beat(16)6.86%
Revenue beat(2)1
Avg Revenue beat(2)-0.55%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)0%
Revenue beat(4)3
Avg Revenue beat(4)0.78%
Min Revenue beat(4)-1.11%
Max Revenue beat(4)3.18%
Revenue beat(8)7
Avg Revenue beat(8)2.25%
Revenue beat(12)9
Avg Revenue beat(12)2.15%
Revenue beat(16)13
Avg Revenue beat(16)2.78%
PT rev (1m)-10.3%
PT rev (3m)-10.3%
EPS NQ rev (1m)-0.7%
EPS NQ rev (3m)-0.7%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.17%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.87
P/FCF N/A
P/OCF N/A
P/B 3.85
P/tB 4.98
EV/EBITDA N/A
EPS(TTM)-3.25
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS5.8
BVpS7.34
TBVpS5.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.09%
ROE -43.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.7%
FCFM N/A
ROA(3y)-27.66%
ROA(5y)-27.95%
ROE(3y)-34.86%
ROE(5y)-34.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y27.06%
F-Score4
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.81%
Cap/Sales 2.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.51
Quick Ratio 4.24
Altman-Z 3.7
F-Score4
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)242.63%
Cap/Depr(5y)230.64%
Cap/Sales(3y)21%
Cap/Sales(5y)18.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.46%
EPS Next Y38.46%
EPS Next 2Y26.3%
EPS Next 3Y19.63%
EPS Next 5Y13.7%
Revenue 1Y (TTM)25.29%
Revenue growth 3Y33.24%
Revenue growth 5Y41.9%
Sales Q2Q%23.23%
Revenue Next Year21.06%
Revenue Next 2Y19.34%
Revenue Next 3Y18.9%
Revenue Next 5Y18.17%
EBIT growth 1Y18.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.75%
EBIT Next 3Y23.75%
EBIT Next 5Y16.16%
FCF growth 1Y69.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.05%
OCF growth 3YN/A
OCF growth 5YN/A